Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2 inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety and tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal carcinoma. AP 12009, administered intravenously, showed a clear proof of concept. Patients with stage IV pancreatic carcinoma, who received AP 12009 for seven days every other week as second or third line therapy, had a median survival time of 29.6 weeks (6.8 months) after start of AP 12009 treatment. One of these patients with several liver metastases even experienced a complete response. Efficacy and safety results of the multicenter Phase I/II study were published today at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA (1).

In the open-label, multicenter, dose-escalation Phase I/II study patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal carcinoma were included. So far 25 patients have been treated in six cohorts. The first four cohorts received AP 12009 as 7-day on, 7-day off cycles. For this schedule, the maximum tolerated dose (MTD) was reached with two grade III thrombocytopenias as dose-limiting toxicities (DLT). These were self-limiting and required no therapeutic intervention. The third DLT was a grade III rash. Thus, the compound AP 12009 revealed excellent safety and tolerability. Very encouraging case reports were observed. One patient, diagnosed with stage IV malignant melanoma, survived more than 60 weeks after the start of AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had a complete response and is still alive as of March 2008 148 weeks (34 months) after the start of treatment with AP 12009.

After reaching the MTD with the 7-day on, 7-day off schedule, a second schedule with 4-day on, 10-day off cycles was initiated. Two cohorts with a total of seven patients h
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  The National Association of Drug Diversion Investigators ... Kentucky,s real-time, stop-sale pseudoephedrine ... Precursor Log Exchange (NPLEx) system automatically blocks unlawful ... helps flag meth offenders for law enforcement. Police ... "watch lists" that notify them via email when ...
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. , ... metagenomic services and data analysis, was the genomic sequencing ... ) Phase I/II clinical trial of SER 109, an ... Clostridium difficile infections (CDI). Metanome ... Health,s R&D and clinical programs. Such genomic characterization has ...
(Date:10/25/2014)... October 24, 2014 ... has announced the addition of the  "Global ...  report to their offering.  ... Chinese Acne Medication Industry Report 2014 is ... current state of the global acne medication ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... , SAN DIEGO, Sept. 11 Calixa ... development and commercialization of novel antibiotics for the treatment ... in 20 posters at the Interscience Conference on Antimicrobial ... San Francisco on September 12 to 15, 2009. ...
... , , , ... preliminary schedule of events at the Cardiovascular Research Foundation,s (CRF) ... September 21st to Friday, September 25th, in San Francisco, CA. ... the world,s largest events for those performing cardiac diagnostics and ...
Cached Medicine Technology:Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2
(Date:10/25/2014)... 26, 2014 Top 10 Best SEO ... the world. The site has recently compared many hosting ... HostMonster are among the most reliable Linux web hosting ... Top 10 Best SEO Hosting says, “The hosting suppliers ... companies who outperform their competitors on hosting features, uptime ...
(Date:10/25/2014)... The global HCIT outsourcing market is ... reach $50.4 billion by 2018 from $35 billion in ... pharmaceutical industry are driving the HCIT outsourcing market. These ... focus on core business, reduce operational and maintenance costs, ... reducing hiring and training costs), share risk, and quickly ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
Breaking Medicine News(10 mins):Health News:Top 10 Best SEO Hosting Announces That GreenGeeks.com And HostMonster Are Among The Most Reliable Linux Web Hosting Companies In 2014 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... infected with HIV in the UK rose last year to ... not know they are carrying the disease, a report said ... and nearly three-quarters of those were probably contracted in Africa., ... HIV sufferers had risen last year from an estimated 53,000 ...
... of anti-depressant medication and lifestyle change may be it is ... enjoy a splendid ride with a dolphin to help ease ... of biophilia that illustrates the dependence of human health on ... patients with mild to moderate depression were chosen for the ...
... Scientific Advisory Committee on Nutrition in the UK has said ... born with birth defects if folic acid were to be ... reducing commonly found neural tube defects like the spina bifida. ... be avoided if this simple precaution were to be taken. ...
... A new study reveals that antibiotics if taken limitlessly ... more than 10 times during childhood can increase the ... lymphatic system. , The study, conducted by Ellen ... Centre in Fremont, also found heavy use of non-steroidal ...
... its toll on Hong Kong teachers, with one in three ... ,Shouting at students in the class is affecting the ... said dry throats and husky and harsh voices were among ... developed voices like men., ,Researchers claim the problem ...
... Bacteria have been long regarded as something, only capable ... might soon change.// Thanks to the fervent efforts of ... UCSF who have created the first-ever bacterial photographs. ... at promoting the construction of simple biological machines is ...
Cached Medicine News:Health News:Swimming With Dolphins Can Help Ease Depression 2Health News:Bacterial Photographs Created By Student Scientists! 2
... watt halogen light source with ... ,SOLOS Endoscopy shares your commitment ... the highest quality care available ... development of advanced surgical instruments ...
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... camera system offers the latest technology ... controller. Equipped with many of the ... expensive camera controllers, including edge enhancement, ... The controller is compatible and interchangeable ...
... Camera Systems provide the advanced functionality ... need for advanced training. Programmable, easy ... the flexibility needed to accommodate the ... Compatible with both autoclavable and non-autoclavable ...
Medicine Products: